Clinical trials
Plasma Cell Myeloma clinical trials
Below are recruiting plasma cell myeloma clinical trials, each written for real people, not researchers. We’re tracking 115 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03858205Recruiting
Low-dose radiation to relieve pain from bone tumors
This trial studies whether low-dose radiation can reduce pain from a specific bone lesion caused by multiple myeloma. It may help people whose main problem is painful bone metastasis, with targeted treatment to the painful spot.
Duarte, CaliforniaAges 18 years+ - NCT07519187RecruitingEarly Phase 1
CAR-T Cell Therapy for Hard-to-Treat Blood Cancers
This trial tests a new type of cell therapy called CAR-T cells that are designed to recognize and attack cancer cells in patients with multiple myeloma, plasmacytoma, plasma cell leukemia, or light chain amyloidosis that have not responded well to previous treatments. The goal is to see if this approach can help patients whose cancers have become resistant to standard medicines.
Chengdu, ChengduAges 18–75 - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT04643002RecruitingPhase 1/Phase 2
Isatuximab added to other drugs for relapsed myeloma
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
Atlanta, GeorgiaAges 18 years+ - NCT06870760Recruiting
Early blood cancer detection in Charlotte firefighters
This study looks at firefighters to find early signs of blood cancers before they become serious. It aims to learn how to catch these cancers earlier, so they can be treated sooner.
Charlotte, North CarolinaAges 40–49 - NCT05136807Recruiting
Quality of life study for people with MGUS or smoldering myeloma
This study looks at how patients feel day to day (quality of life) while they are monitored or treated for MGUS or smoldering multiple myeloma. It is designed for people who do NOT yet have “myeloma defining events” or amyloidosis, because the goal is to understand well-being in earlier disease stages.
Houston, TexasAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Birmingham, AlabamaAges Any age - NCT06644625Recruiting
CHAAMP study: MGUS screening for Black adults and relatives
This study screens for MGUS, a precursor to certain blood cancers, in people who are Black or African American, or who have a close relative with a plasma cell disorder. If MGUS is found, you may be invited to continue in the study to monitor your health.
Charlotte, North CarolinaAges 30 years+ - NCT07649525RecruitingPhase 3
Personalized myeloma treatment based on response and fitness
This trial tests whether tailoring myeloma treatment based on how well you respond to initial therapy and your overall health status can improve outcomes. You'll receive standard first-line treatment (three drugs: daratumumab, lenalidomide, and dexamethasone) and then be assigned to a personalized pathway based on your response and fitness level.
BristolAges 18 years+ - NCT03616483Recruiting
Indiana Myeloma Registry for blood cancer-related diagnoses
This registry collects information from adults with certain plasma-cell conditions like MGUS, smoldering multiple myeloma, multiple myeloma, plasmacytoma, or primary amyloidosis. It may help researchers learn more about these diseases and improve future care.
Indianapolis, IndianaAges 18 years+ - NCT05556928Recruiting
Cancer and aging study for adults with blood cancers
This study builds a registry to learn how aging and “resilience” relate to outcomes in people with blood cancers. You may be asked to complete questionnaires during UAB visits, which can help researchers better understand needs in older adults.
Birmingham, AlabamaAges 50 years+ - NCT01137825Recruiting
Older patient cancer registry for a health check
This study is a registry that collects information from older adults who may be dealing with cancer. It includes a short health and function check to help doctors understand needs and guide care, even for people who turn out not to have cancer.
Boone, North CarolinaAges 65 years+ - NCT01137643Recruiting
Sharing blood and tissue samples for blood cancer research
This trial collects tissue, blood, and other body fluid samples from people with blood-related cancers. The goal is to help researchers study these diseases by building a source of samples for future testing.
Chapel Hill, North CarolinaAges 18–120 - NCT07179679RecruitingPhase 1
Study of a new shot for multiple myeloma
This trial tests a new injectable treatment for people with multiple myeloma that has come back or not responded to previous therapies. It aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06461988RecruitingPhase 2
Talquetamab and lenalidomide after stem cell transplant for myeloma
This trial tests combining two drugs, talquetamab and lenalidomide, as maintenance therapy after a stem cell transplant for multiple myeloma. The goal is to see if this combination helps keep the cancer from coming back.
Palo Alto, CaliforniaAges 18 years+ - NCT06140524RecruitingPhase 2
Study of Linvoseltamab for high-risk MGUS or smoldering myeloma
This trial tests if linvoseltamab can remove abnormal plasma cells that might turn into multiple myeloma. It is for patients with high-risk MGUS (a precancerous condition) or non-high-risk smoldering myeloma who have not yet developed active myeloma.
Baltimore, MarylandAges 18 years+ - NCT01408225Recruiting
Myeloma and amyloidosis patient data and sample registry
This study collects health information and, if needed, samples from people diagnosed with certain blood disorders related to plasma cells. Sharing your information may help researchers better understand these diseases and improve future care.
Columbus, OhioAges 18 years+ - NCT05976555RecruitingPhase 1
CAR T-cell therapy for relapsed myeloma after multiple treatments
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
Milwaukee, WisconsinAges 18–80 - NCT03127761Recruiting
Transplant study for Medicare patients with advanced myeloma
This study looks at outcomes of an allogeneic transplant (a donor-based transplant) in people with stage II–III multiple myeloma or primary plasma cell leukemia who have Medicare. It may help doctors better understand which patients benefit and what to expect before and after transplant.
Minneapolis, MinnesotaAges Any age - NCT06523699RecruitingPhase 1
Testing interleukin-7 after stem cell transplant for myeloma
This study tests whether a drug called interleukin-7 (CYT107) can help your immune system recover faster and clear myeloma cells better after a stem cell transplant. You would receive CYT107 injections after your transplant, and the study will check if this improves your long-term outcome.
St Louis, MissouriAges 18 years+ - NCT03562169RecruitingPhase 3
Ixazomib with your own stem cell transplant for relapsed myeloma
This trial studies whether adding ixazomib (an oral drug) to a transplant using your own stem cells can control relapsed multiple myeloma better. It may help by strengthening anti-myeloma treatment after the transplant, aiming to delay disease progression.
AberdeenAges 18 years+ - NCT05521802RecruitingPhase 1/Phase 2
Testing a new CAR-T therapy for relapsed myeloma
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
TianjinAges 18 years+ - NCT05913804RecruitingPhase 1
Study of YTS104 cell therapy for hard-to-treat myeloma
This Phase 1 study tests an injected cell therapy (YTS104) for people with multiple myeloma that has come back or did not respond after several prior treatments. The goal is to see whether the treatment is safe and may help control the disease.
TianjinAges 18–75 - NCT02012699Recruiting
Cancer registry for people with or at risk of cancer
This trial collects health information and samples (a “cancer repository”) to help researchers study cancer and cancer risk. You may be able to join if you’ve had cancer before or if you’re at higher risk or have concerning findings.
Greenwood Village, ColoradoAges 19–110
Hear when a new Plasma Cell Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for plasma cell myeloma?
- Yes. Clin2 currently lists 115 recruiting plasma cell myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a plasma cell myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a plasma cell myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.